PHIO Insider Trading
Insider Ownership Percentage: 0.89%
Insider Buying (Last 12 Months): $34,511.00
Insider Selling (Last 12 Months): $0.00
Phio Pharmaceuticals Share Price & Price History
Current Price: $1.35
Price Change: ▲ Price Increase of +0.06 (4.65%)
As of 12/4/2025 05:00 PM ET
Phio Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/21/2025 | Robert J Bitterman | CEO | Buy | 5,000 | $1.14 | $5,700.00 | 281,421 |  |
| 11/18/2025 | Robert J Bitterman | CEO | Buy | 5,000 | $1.27 | $6,350.00 | 276,421 | |
| 6/10/2025 | Robert J Bitterman | CEO | Buy | 2,000 | $2.42 | $4,840.00 | 27,149 | |
| 6/10/2025 | Robert L Ferrara | Director | Buy | 2,500 | $2.42 | $6,050.00 | 15,666 | |
| 6/9/2025 | Robert J Bitterman | CEO | Buy | 1,500 | $2.75 | $4,125.00 | 25,149 | |
| 5/22/2025 | Robert J Bitterman | CEO | Buy | 1,200 | $1.78 | $2,136.00 | 23,649 | |
| 5/21/2025 | Robert J Bitterman | CEO | Buy | 3,000 | $1.77 | $5,310.00 | 22,449 | |
| 6/6/2024 | Robert J Bitterman | CEO | Buy | 111 | $6.75 | $749.25 | 2,221 | |
| 2/26/2024 | Robert J Bitterman | CEO | Buy | 277 | $8.19 | $2,268.63 | 2,110 | |
| 6/30/2023 | Robert J Bitterman | CEO | Buy | 111 | $25.92 | $2,877.12 | 2,023 | |
| 6/14/2023 | Robert L Ferrara | Director | Buy | 222 | $27.90 | $6,193.80 | 666 | |
| 12/14/2022 | Robert J Bitterman | Chairman | Buy | 222 | $3.51 | $779.22 | 8,282 | |
| 12/7/2022 | Robert J Bitterman | Chairman | Buy | 222 | $3.51 | $779.22 | 8,060 | |
Phio Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 8/8/2025 | Cetera Investment Advisers | 32,500 | $76K | 0.0% | -15.6% | 0.677% |  |
| 8/8/2025 | Geode Capital Management LLC | 57,694 | $0.14M | 0.0% | +38.7% | 1.202% | |
| 2/11/2025 | Virtu Financial LLC | 40,910 | $74K | 0.0% | N/A | 0.594% | |
| 8/14/2023 | Anson Funds Management LP | 22,571 | $65K | 0.0% | N/A | 1.505% | |
| 8/10/2023 | Cetera Investment Advisers | 10,666 | $31K | 0.0% | N/A | 0.711% | |
| 8/2/2023 | Bank of Montreal Can | 10,000 | $38K | 0.0% | N/A | 0.667% | |
| 8/11/2022 | Cetera Investment Advisers | 75,000 | $53K | 0.0% | -16.7% | 0.549% | |
| 11/16/2021 | Cetera Investment Advisers | 30,000 | $61K | 0.0% | N/A | 0.222% | |
| 11/9/2021 | BlackRock Inc. | 35,592 | $72K | 0.0% | -17.8% | 0.263% | |
Data available starting January 2016
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Read More on Phio Pharmaceuticals
Volume
377,574 shs
Average Volume
564,433 shs
Market Capitalization
$14.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.92
Who are the company insiders with the largest holdings of Phio Pharmaceuticals?
